Clarity Pharmaceuticals Ltd (ASX:CU6)

Market Cap	713.40M
Revenue (ttm)	10.78M
Net Income (ttm)	-48.70M
Shares Out	321.35M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,230,242
Average Volume	3,341,946
Open	2.280
Previous Close	2.220
Day's Range	2.280 - 2.680
52-Week Range	1.430 - 8.980
Beta	1.65
RSI	49.27
Earnings Date	May 29, 2025

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 50
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CU6

Financial Performance

In 2024, Clarity Pharmaceuticals's revenue was 11.51 million, an increase of 17.41% compared to the previous year's 9.80 million. Losses were -42.32 million, 72.0% more than in 2023.